Drugs / AMG 794
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05317078 | Feb → Dec 2023 | malignant epithelial tumor of ovary, non-small cell lung carcinoma | Amgen | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-08 | Amgen | Results AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022 amgen.com ↗
Notable data from Amgen 's oncology pipeline includes the first disclosure of preclinical results from AMG 794, a half-life extended (HLE) bispecific T-cell engager (BiTE ® ) molecule targeting Claudin 6 (CLDN6) in NSCLC and epithelial ovarian cancer, and TNB-928b, a T-cell engaging bispecific antibody utilizing a bivalent tumor-selective folate receptor alpha binding arm for the treatment of ovarian cancer. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-08 | Amgen | AMGEN TO PRESENT LONG-TERM OUTCOMES FOR LUMAKRAS® (SOTORASIB) IN KRAS G12C-MUTATED NSCLC AT AACR 2022 amgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 794 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05317078 ↗ |
| Route | Intravenous | “Short-term intravenous (IV) infusion.” NCT05317078 ↗ |